Steven Kernerman, DO
Allergy & Immunology · Spokane, WANPI 1477544435
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,191, more than ten times the $37 reported in 2019.
Across 153 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$748
- GSK$433
- Sanofi$286
- Blueprint Medicines Corporation$234
- Amgen$222
- Merck$157
- plus $1K from 19 others
What the payments were for
- Consulting fees$261%
- Food & beverage$3,30999%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 40 | $748 |
| GSK | 23 | $433 |
| Sanofi | 14 | $286 |
| Blueprint Medicines Corporation | 8 | $234 |
| Amgen(2 entities) | 11 | $222 |
| Merck | 1 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $147 |
| Pharming Healthcare, Inc. | 7 | $143 |
| Pfizer | 6 | $134 |
| Genentech USA, Inc. | 5 | $95 |
| Bio Products Laboratory USA, Inc. | 4 | $84 |
| Regeneron Healthcare Solutions, Inc. | 3 | $74 |
| Novartis | 4 | $73 |
| CSL Behring | 3 | $71 |
| Grifols USA, LLC | 3 | $67 |
| Incyte Corporation | 3 | $56 |
| Octapharma USA, Inc. | 2 | $54 |
| Jubilant Hollisterstier LLC | 1 | $52 |
| AbbVie | 2 | $51 |
| Tersera Therapeutics LLC | 1 | $39 |
| Biocryst US Sales Co., LLC | 1 | $33 |
| ADMA Biomanufacturing LLC | 1 | $26 |
| Alk-abello, Inc | 1 | $24 |
| Galderma Laboratories, L.p. | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
How this compares
$3,344 in reported general payments places this provider in the 65th percentile of 81 allergy & immunology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TakhzyroLanadelumab-Flyo | 11 | $550,512 |
| Dupixent SyringeDupilumab | 29 | $113,868 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 20 | $106,848 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 11 | $39,007 |
| Spiriva RespimatTiotropium Bromide | 27 | $24,811 |
| DuleraMometasone/Formoterol | 39 | $19,762 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $17,175 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $16,678 |
| Incruse ElliptaUmeclidinium Bromide | 33 | $16,457 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $15,612 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 75 | $14,916 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 26 | $14,279 |
| Arnuity ElliptaFluticasone Furoate | 43 | $10,516 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $10,081 |
| Epinephrine | 20 | $4,380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Takhzyro | $147 | $550,51211 claims |
| PfizerPanzyga | $134 | $106,84820 claims |
| GSKTrelegy Ellipta, Incruse Ellipta, Breo Ellipta, Arnuity Ellipta | $433 | $59,263125 claims |
| Grifols USA, LLCGamunex-C | $67 | $39,00711 claims |
| MerckDulera | $157 | $19,76239 claims |
| AstraZenecaSymbicort | $748 | $17,17542 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 81 allergy & immunology providers in Washington.
Other allergy & immunology in Spokane
- Richard GowerSpokane$104K
- Ronald EnglandSpokane$6K
- Kerry DrainSpokane$2K
- Rayna TraenSpokane$1K
- Taiil SongLakewood$192K
- Frank VirantSeattle$107K
- Leonard AltmanSeattle$81K
- Daniel PetroniSeattle$68K
- David McGarrySpokane Valley$66K
- Rahool DaveSeattle$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.